MedTrace Logo

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

NCT06351020 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 387

Last updated 2026-02-06

No results posted yet for this study

Summary

This study will assess the efficacy and safety of LM-302 Versus Treatment of Physician's Choice (TPC) in Subjects With locally advanced or metastatic, Claudin (CLDN) 18.2-positive, Gastric or Gastroesophageal Junction Adenocarcinoma who have progressed on or after 2 lines of systemic therapy

Conditions

  • Locally Advanced or Metastatic GC and GCJ Adenocarcinoma

Interventions

DRUG

LM-302

LM-302 intravenous-injection every 2 weeks on Day 1 of each 14-day cycle

DRUG

Apatinib

The subjects will receive Apatinib orally,qd

DRUG

Irinotecan

The subjects will receive Irinotecan intravenous-injection,every 2 weeks on Day 1 of each 14-day cycle

Sponsors & Collaborators

  • LaNova Medicines Zhejiang Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Chunmei Bai · Peking Union Medical College Hospital

  • Jin Li · Shanghai East Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-24
Primary Completion
2026-11-10
Completion
2026-12-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06351020 on ClinicalTrials.gov